GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the overall response rate of Obinutuzumab (GA101) in
combination with Pixantrone in patients with relapsed aggressive B-cell lymphoma. 70 patients
with diffuse large B-cell lymphoma, follicular lymphoma grade IIIB or transformed indolent
lymphoma will receive up to 6 cycles of the described combination regimen. Follow up visits
are scheduled for up to 3 years.